Patients diagnosed with localized or regionally advanced gynecological cancers are often considered candidates for EBRT. This includes women with early-stage cervical cancer who may receive EBRT as part of a combined treatment approach, as well as those with more advanced stages where EBRT is used to shrink tumors before surgery or as a primary treatment modality.
